Core Viewpoint - The approval of the inhalation powder formulation of Nintedanib by the National Medical Products Administration of China marks a significant advancement for the company, as it is the first inhalation formulation approved for clinical trials in China for the treatment of pulmonary fibrosis [1] Company Summary - The stock price of CSPC Pharmaceutical Group (01093) increased by over 4%, reaching a price of HKD 8.81 with a trading volume of HKD 595 million [1] - The inhalation formulation of Nintedanib is a multi-tyrosine kinase inhibitor that can slow the progression of idiopathic pulmonary fibrosis (IPF) [1] - Compared to the oral soft capsule formulation currently on the market, the inhalation product offers significant advantages, including improved lung exposure, better lung function, reduced systemic exposure, and significantly lower gastrointestinal side effects [1] Clinical Research Summary - Preclinical studies indicate that the inhalation formulation can achieve the same therapeutic effect at a dosage of 1/200 of the oral formulation, demonstrating good safety and efficacy [1]
港股异动 | 石药集团(01093)午前涨超4% 乙磺酸尼达尼布吸入粉雾剂获批临床试验